Infliximab bests conventional treatment to achieve Crohn's disease remission in kids: BMJ
Netherlands: First-line infliximab (FL-IFX) is more effective than conventional treatment in achieving and maintaining remission in pediatric patients with newly diagnosed moderate-to-severe Crohn's disease (CD), finds a recent study in the BMJ journal Gut. Maria M E Jongsma,
In newly diagnosed paediatric patients with moderate-to-severe CD, infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and immunomodulator therapies have failed. Maria M E Jongsma, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands, and colleagues aimed to investigate whether starting first-line IFX (FL-IFX) is more effective to achieve and maintain remission than conventional treatment.
The multicentre open-label randomised controlled trial included 100 untreated patients with a new diagnosis of CD (3–17 years old, weighted Paediatric CD Activity Index score (wPCDAI) >40). They were assigned to groups that received five infusions of 5 mg/kg IFX at weeks 0, 2, 6, 14 and 22 (FL-IFX; n=50) or EEN or oral prednisolone (1 mg/kg, maximum 40 mg) (conventional; n=50). Four patients did not receive treatment as per protocol.
The primary outcome was clinical remission on azathioprine, defined as a wPCDAI <12.5 at week 52, without need for treatment escalation, using intention-to-treat analysis.
Key findings of the study include:
- At week 10, a higher proportion of patients in the FL-IFX group than in the conventional group achieved clinical (59% vs 34%, respectively) and endoscopic remission (59% vs 17%, respectively).
- At week 52, the proportion of patients in clinical remission was not significantly different.
- 19/46 (41%) patients in the FL-IFX group were in clinical remission on azathioprine monotherapy without need for treatment escalation vs 7/48 (15%) in the conventional group.
"FL-IFX was superior to conventional treatment in achieving short-term clinical and endoscopic remission, and had greater likelihood of maintaining clinical remission at week 52 on azathioprine monotherapy," wrote the authors.
The study titled, "First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial," is published in the BMJ journal Gut.
DOI: https://gut.bmj.com/content/early/2020/12/31/gutjnl-2020-322339
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.